Citi Keeps Their Buy Rating on Oshkosh (OSK)
Citi analyst Kyle Menges maintained a Buy rating on Oshkosh (OSK – Research Report) today and set a price target of $130.00. The company's shares closed today at $108.67.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Menges is a 3-star analyst with an average return of 4.6% and a 65.45% success rate. Menges covers the Industrials sector, focusing on stocks such as Cummins, Deere, and Oshkosh.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oshkosh with a $116.92 average price target.
OSK market cap is currently $7.02B and has a P/E ratio of 11.65.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Citi Expresses Optimism for Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Long Term Growth Stocks to Invest in Right Now. On June 25, Citi reported that 'compelling' data shows that Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NVO) have turned obesity into a treatable disease from a lifestyle-based condition. The firm models more than $40 billion in obesity sales by 2030, well above the consensus estimates of $25 billion. Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a 'dynamic' consumer-centric market is possible, and LillyDirect by Eli Lilly and Company (NYSE:LLY) is well-positioned to connect high consumer visibility for orforglipron with global access. In a research note, Citi further stated that it estimated penetration rates via income-based tiers for pricing and out-of-pocket costs in low- and mid-body mass index patients. The results place Eli Lilly and Company's (NYSE:LLY) consumer platform opportunity at $15B, which is not assumed in the firm's model. It thus believes that Eli Lilly and Company's (NYSE:LLY) is in a position to expedite access outside the US, employing a centralized out-of-pocket payment model instead of the traditional country-by-country launch. It contended that an 'income-based tiered pricing of orforglipron via LillyDirect could unlock unprecedented volume, all the while allowing it to maintain overall pricing power.' Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies. Investors are bullish on Eli Lilly and Company (NYSE:LLY) due to its in-demand GLP-1 drugs, used to treat diabetes and obesity, which are still in their early growth stages, and the company's strong financials. While we acknowledge the potential of LKQ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Business Insider
3 hours ago
- Business Insider
RELX plc (RLXXF) Receives a Hold from Kepler Capital
Kepler Capital analyst Conor O'Shea maintained a Hold rating on RELX plc (RLXXF – Research Report) on June 26 and set a price target of p4,060.00. The company's shares closed yesterday at $53.50. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, O'Shea is a 4-star analyst with an average return of 8.0% and a 55.40% success rate. O'Shea covers the Communication Services sector, focusing on stocks such as Ipsos SA, Publicis Groupe, and Informa. The word on The Street in general, suggests a Strong Buy analyst consensus rating for RELX plc with a $62.26 average price target. RLXXF market cap is currently $97.5B and has a P/E ratio of 39.86. Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RLXXF in relation to earlier this year.
Business Insider
3 hours ago
- Business Insider
Kepler Capital Remains a Hold on SSAB Corporation (0KII)
In a report released on June 26, Boris Bourdet from Kepler Capital maintained a Hold rating on SSAB Corporation (0KII – Research Report), with a price target of SEK60.00. The company's shares closed last Thursday at SEK55.64. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Bourdet is a 3-star analyst with an average return of 6.2% and a 68.00% success rate. Bourdet covers the Industrials sector, focusing on stocks such as thyssenkrupp, Salzgitter, and Kloeckner & Co. SE. SSAB Corporation has an analyst consensus of Hold, with a price target consensus of SEK68.20. Based on SSAB Corporation's latest earnings release for the quarter ending March 30, the company reported a quarterly revenue of SEK25.52 billion and a net profit of SEK1.13 billion. In comparison, last year the company earned a revenue of SEK27.15 billion and had a net profit of SEK2.57 billion
